Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesityinvestors.comThe company just initiated two Phase 3 studies of its weekly under-the-skin shot to stoke weight loss.
What's Going On With Viking Therapeutics Stock On Wednesday?benzinga.comViking Therapeutics begins Phase 3 trials for VK2735, testing weekly injections in over 5,000 adults with obesity or type 2 diabetes over 78 weeks.
Amgen Expands Development Plans For Highly Anticipated Obesity Druginvestors.comAmgen is expanding its plans for weight-loss drug, MariTide, with a trio of upcoming Phase 3 studies.
Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Priceinvestors.comNovo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Fridayfool.comGLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors.
